EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...
pharmaphorum22h
After earlier rejection, high-dose Eylea clears FDA
Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...
PharmiWeb17h
Formycon reports on a successful financial year 20…
Annual Report/Annual ResultsFormycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CESTThe ...
Alvotech Reports Record Results for 2024 and Provides Business Update
Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...